

Momenta Pharmaceuticals Therapeutic and Drug Pipeline Review H1

*Momenta Pharmaceuticals
Pharmaceutical and Healthcare Pipeline
Review H1*

PUNE, INDIA, February 27, 2017
/EINPresswire.com/ -- [Momenta
Pharmaceuticals, Inc. - Product Pipeline
Review - 2016](#)

Summary

The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/606177-momenta-pharmaceuticals-inc-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc.
- The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages



**WISE GUY
REPORTS**

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The report assesses Momenta Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Momenta Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Momenta Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points

Table of Contents 2

List of Tables 5

List of Figures 5

Momenta Pharmaceuticals, Inc. Snapshot 6

Momenta Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Momenta Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Momenta Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 12

Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Momenta Pharmaceuticals, Inc. - Drug Profiles 17

adalimumab biosimilar 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

necuparanib 18

Product Description 18

Mechanism of Action 18

R&D Progress 18
...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/606177-momenta-pharmaceuticals-inc-product-pipeline-review-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.